Table of Content

Open Access iconOpen Access

ARTICLE

Apatinib Monotherapy or Combination Therapy for Non-Small Cell Lung Cancer Patients With Brain Metastases

Jianping Xu, Xiaoyan Liu, Sheng Yang, Yuankai Shi

Department of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, P.R. China

Oncology Research 2020, 28(2), 127-133. https://doi.org/10.3727/096504019X15707896762251

Abstract

Apatinib, an oral small molecular receptor tyrosine kinase inhibitor (TKI) developed first in China, exerts antiangiogenic and antineoplastic function through selectively binding and inhibiting vascular endothelial growth factor receptor 2 (VEGFR-2). In this study, we aimed to explore the efficacy and safety profile of apatinib monotherapy, or combined with chemotherapy or endothelial growth factor receptor (EGFR)-TKI in heavily pretreated non-small cell lung cancer (NSCLC) patients with brain metastases. We performed a retrospective analysis for relapsed NSCLC patients with brain metastases from our institute, who received apatinib (250 mg or 500 mg p.o. qd) monotherapy, or combination with EGFR-TKI or chemotherapy as second or more line systemic therapy until disease progression or unacceptable toxicity occurred. The objective response rate (ORR), disease control rate (DCR), median progression-free survival (mPFS), median overall survival (mOS), and safety were analyzed. A total of 26 eligible patients were included: 24 patients diagnosed with adenocarcinoma, 2 with squamous carcinoma, and 14 patients harboring EGFR sensitizing mutations. The mPFS and mOS were 4.93 (range, 0.27−32.91; 95% CI 3.64−6.22) and 14.70 (range, 0.27−32.91; 95% CI 0.27−43.60) months for the whole group. The ORR and DCR were 7.7% (2/26) and 69.2% (18/26) for the entire lesions, and 7.7% (2/26) and 79.6% (20/26) for brain metastases, respectively. Compared with patients who received apatinib monotherapy, patients who received apatinib combination treatment had more favorable mPFS (11.77 vs. 2.27 months, p<0.05) and mOS (24.03 vs. 6.07 months, p<0.05). Treatment-related toxicities were tolerable including grade 1/2 hypertension, hand-and-foot syndrome, fatigue, nausea, liver dysfunction, myelosuppression, skin rash, and palpitation. In conclusion, apatinib exhibited high activity and good tolerance for NSCLC patients with brain metastasis, and it might become a potential choice for metastatic brain tumors in NSCLC patients.

Keywords


Cite This Article

APA Style
Xu, J., Liu, X., Yang, S., Shi, Y. (2020). Apatinib monotherapy or combination therapy for non-small cell lung cancer patients with brain metastases. Oncology Research, 28(2), 127-133. https://doi.org/10.3727/096504019X15707896762251
Vancouver Style
Xu J, Liu X, Yang S, Shi Y. Apatinib monotherapy or combination therapy for non-small cell lung cancer patients with brain metastases. Oncol Res. 2020;28(2):127-133 https://doi.org/10.3727/096504019X15707896762251
IEEE Style
J. Xu, X. Liu, S. Yang, and Y. Shi "Apatinib Monotherapy or Combination Therapy for Non-Small Cell Lung Cancer Patients With Brain Metastases," Oncol. Res., vol. 28, no. 2, pp. 127-133. 2020. https://doi.org/10.3727/096504019X15707896762251



cc This work is licensed under a Creative Commons Attribution 4.0 International License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
  • 563

    View

  • 422

    Download

  • 0

    Like

Share Link